GlassScriptPhysician profile
Vijay Kumar Bahl
NPI 1912084625
$997,685.39
in general payments reported to CMS, 2019-2025
63 companies · $128K in 2025
The $128K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267K · 2020: $141K · 2021: $118K · 2022: $142K · 2023: $80K · 2024: $122K · 2025: $128K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $274K · Travel and Lodging: $33K · Food and Beverage: $20K · Consulting Fee: $3,336 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $273,864.25 |
| Travel and Lodging | $32,702.32 |
| Food and Beverage | $19,761.89 |
| Consulting Fee | $3,336.00 |
| Education | $193.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $408,366.70 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $152,660.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $99,922.67 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $86,089.78 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $69,374.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $61,578.47 | 2019-2024 | Farxiga, Airsupra, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29,641.79 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Ascendis Pharma Endocrinology INC | $24,955.47 | 2023-2025 | Yorvipath |
| Amarin Pharma, INC. | $16,815.12 | 2019-2022 | |
| Amgen INC. | $15,895.13 | 2019-2025 | Tepezza, Evenity, Repatha |
| Merck Sharp & Dohme LLC | $8,921.26 | 2019-2023 | Steglatro, Verquvo, Steglujan |
| Abbvie INC. | $7,042.65 | 2019-2025 | Ubrelvy, Synthroid |
| Esperion Therapeutics, INC. | $4,400.19 | 2021-2025 | Nexletol |
| Zealand Pharma US, INC. | $1,926.23 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $1,882.20 | 2019-2025 | Unithroid |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,700.51 | 2022-2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $882.81 | 2019-2022 | |
| Cequr Corporation | $867.20 | 2022-2025 | Cequr Simplicity |
| Abbott Laboratories | $753.82 | 2019-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $449.01 | 2019-2025 | Korlym |
| Astellas Pharma US INC | $306.70 | 2023-2025 | Veozah |
| Medtronic, INC. | $302.45 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Inceptiv |
| Novartis Pharmaceuticals Corporation | $211.95 | 2022-2024 | |
| Embecta Corp. | $202.79 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Insulet Corporation | $195.74 | 2019-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $170.10 | 2019-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $164.63 | 2021-2025 | Recorlev |
| Tandem Diabetes Care, INC. | $149.46 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $148.24 | 2021-2023 | Afrezza |
| Madrigal Pharmaceuticals | $145.41 | 2025 | Rezdiffra |
| Pfizer INC. | $138.38 | 2019-2024 | |
| Medtronic Minimed, INC. | $133.27 | 2019-2020 | |
| Sequel Med Tech, LLC | $122.39 | 2025 | Twiist |
| Horizon Therapeutics Plc | $115.95 | 2022-2023 | Tepezza |
| Antares Pharma, INC. | $110.13 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Kowa Pharmaceuticals America, INC. | $88.21 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $66.71 | 2020-2024 | Camzyos |
| Ibsa Pharma INC. | $59.55 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $58.94 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $52.47 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $42.03 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.86 | 2020 | |
| Arbor Pharmaceuticals, INC. | $39.47 | 2021 | |
| Radius Health, INC. | $38.73 | 2023-2025 | Tymlos |
| Nevro Corp. | $37.80 | 2021-2022 | |
| Glaxosmithkline, LLC. | $37.47 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $36.41 | 2019-2021 | |
| Beta Bionics, INC. | $31.11 | 2023-2024 | Ilet Bionic Pancreas |
| Averitas Pharma INC. | $30.26 | 2025 | Qutenza |
| Acerus Pharmaceuticals Corporation | $29.97 | 2020-2021 | |
| Vivus LLC | $26.42 | 2019-2021 | |
| Valeritas, INC. | $23.17 | 2019 | |
| Endo Pharmaceuticals INC. | $21.66 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $20.50 | 2025 | Imcivree |
| Ultragenyx Pharmaceutical INC. | $19.88 | 2022 | |
| Kyowa Kirin, INC. | $19.81 | 2024 | Crysvita |
| Aytu Biopharma, INC. | $19.50 | 2019 | |
| Lifescan, INC. | $19.41 | 2020 | |
| Exact Sciences Corporation | $19.27 | 2025 | The Cologuard Plus Collection Kit |
| Recordati_rare_diseases_inc. | $17.97 | 2023 | Signifor Lar, Isturisa |
| Verity Pharmaceuticals INC. | $17.07 | 2024 | Tlando |
| Shire North American Group INC | $15.31 | 2019 | |
| Halozyme INC | $13.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Bahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.